Evinacumab
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody) . Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia[1].
Product Specifications
CAS Number
1446419-85-7
Product Name Alternative
REGN1500
UNSPSC
12352203
Target
ANGPTL
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/evinacumab.html
Purity
99.24
Solubility
10 mM in DMSO
Smiles
[Evinacumab]
Molecular Weight
(144.5 kDa)
References & Citations
[1]Gusarova V, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015 Jul;56 (7) :1308-17.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
C8931 96 Tests
Differentially expressed in FDCP 6 homolog (DEF6) Human ELISA Kit
Sign In for Pricing
View Details 
147580 100 µg
ABHD4, Control Peptide (abhydrolase domain containing 4, Alpha/beta-hydrolase 4, FLJ12816, Lyso-N-acylphosphatidylethanolamine lipase) discontinued
Sign In for Pricing
View Details